Abstract
Cholinergic deficit is a cardinal feature of Alzheimers disease, and cholinesterase inhibitors represent one of the most prominent means of mitigating this dysfunction. Cholinesterase inhibitors provide mild symptomatic relief, although they lose their efficacy over time most likely because they are not disease-modifying agents. An alternative strategy for restoring cholinergic function and attenuating the cognitive decline involves acting on the receptors on which acetylcholine acts. Stimulation of muscarinic acetylcholine receptors and in particular the M1 subtype has been shown to have a beneficial effect in restoring cognition in patients with Alzheimers disease and in attenuating Aβ and tau pathology in different animal models. In this review, we discuss the role of M1 agonists as a potential disease – modifying therapy for Alzheimers disease.
Keywords: M1 Agonists, Alzheimer's disease, cholinesterase inhibitors, acetylcholine receptors, cholinergic neurons
Current Alzheimer Research
Title: M1 Agonists as a Potential Disease-Modifying Therapy for Alzheimers Disease
Volume: 6 Issue: 2
Author(s): Antonella Caccamo, Abraham Fisher and Frank M. LaFerla
Affiliation:
Keywords: M1 Agonists, Alzheimer's disease, cholinesterase inhibitors, acetylcholine receptors, cholinergic neurons
Abstract: Cholinergic deficit is a cardinal feature of Alzheimers disease, and cholinesterase inhibitors represent one of the most prominent means of mitigating this dysfunction. Cholinesterase inhibitors provide mild symptomatic relief, although they lose their efficacy over time most likely because they are not disease-modifying agents. An alternative strategy for restoring cholinergic function and attenuating the cognitive decline involves acting on the receptors on which acetylcholine acts. Stimulation of muscarinic acetylcholine receptors and in particular the M1 subtype has been shown to have a beneficial effect in restoring cognition in patients with Alzheimers disease and in attenuating Aβ and tau pathology in different animal models. In this review, we discuss the role of M1 agonists as a potential disease – modifying therapy for Alzheimers disease.
Export Options
About this article
Cite this article as:
Caccamo Antonella, Fisher Abraham and LaFerla M. Frank, M1 Agonists as a Potential Disease-Modifying Therapy for Alzheimers Disease, Current Alzheimer Research 2009; 6 (2) . https://dx.doi.org/10.2174/156720509787602915
DOI https://dx.doi.org/10.2174/156720509787602915 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemical Composition and Biological Effects of Essential Oils from Some Aromatic and Medicinal Plants
The Natural Products Journal Sirtuins: Common Targets in Aging and in Neurodegeneration
Current Drug Targets The Potential Mechanisms of Exercise-induced Cognitive Protection: A Literature Review
Current Pharmaceutical Design The Serum Protein and Lipid Oxidation Marker Levels in Alzheimers Disease and Effects of Cholinesterase Inhibitors and Antipsychotic Drugs Therapy
Current Alzheimer Research The Spleen Tyrosine Kinase (Syk) in Human Disease, Implications for Design of Tyrosine Kinase Inhibitor Based Therapy
Current Pharmaceutical Design The prediction of response to Galantamine treatment in Patients with mild to moderate Alzheimer’s Disease
Current Alzheimer Research From Protein Communication to Drug Discovery
Current Topics in Medicinal Chemistry Employing New Cellular Therapeutic Targets for Alzheimers Disease: A Change for the Better?
Current Neurovascular Research Improving Cognition through Dance in Older Filipinos with Mild Cognitive Impairment
Current Alzheimer Research Dissecting the Biological Effects of Isoflurane through the Mechanistic Target of Rapamycin (mTOR) and microRNAs (miRNAs)
Current Neurovascular Research TNF-α and Ghrelin: Opposite Effects on Immune System, Metabolism and Mental Health
Protein & Peptide Letters Identification of a Missense Mutation in the α-galactosidase A Gene in a Chinese Family with Fabry Disease
Current Genomics Cyclic Nucleotides Signaling and Phosphodiesterase Inhibition: Defying Alzheimer’s Disease
Current Drug Targets The Possibility of Therapeutic Drug Monitoring of the Most Important Interactions in Nursing Homes
Current Clinical Pharmacology Anti-Inflammatory Agents in Parkinsons Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Role of TMP21 in Trafficking and Amyloid-β Precursor Protein (APP) Processing in Alzheimer’s Disease
Current Alzheimer Research Chemokines and Brain Functions
Current Drug Targets - Inflammation & Allergy Editorial [‘Current Alzheimer Research’ Helps Accelerate the Progress of the Field]
Current Alzheimer Research Disrupting Self-Assembly and Toxicity of Amyloidogenic Protein Oligomers by “ Molecular Tweezers” - from the Test Tube to Animal Models
Current Pharmaceutical Design Genomic and Molecular Characterization of Alzheimer Disease
Current Psychiatry Reviews